Oncobeam

German companies Merck and Sysmex Inostics have secured CE mark approval for their new liquid biopsy RAS biomarker test.

In 2014, the companies entered into an agreement to collaborate on developing the liquid biopsy test and established the first test centre for research use at the Vall d’Hebron Institute of Oncology in Barcelona, Spain.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

With the CE mark, the test will now be made available to patients with metastatic colorectal cancer (mCRC) in Europe, Asia and Australia.

Known as OncoBEAM RAS CRC assay, the testing technology can be leveraged to determine which patients would benefit from anti-epidermal growth factor receptor (anti-EGFR) therapies, such as Erbitux.

Merck biopharma business chief marketing and strategy officer Rehan Verjee said: "The CE mark approval of the liquid biopsy RAS biomarker test is therefore a pivotal milestone for patients with metastatic colorectal cancer, as it allows for informed and rapid treatment decisions.

"We, with our partner Sysmex Inostics, can now start making this test available to more patients around the world."

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
"We, with our partner Sysmex Inostics, can now start making this test available to more patients around the world."

The liquid biopsy RAS biomarker test is a comprehensive 34-mutation panel based on BEAMing (beads, emulsion, amplification and magnetics) technology.

The test can be conducted on a small blood sample of 10ml replacing the requirement of a tissue biopsy, to determine the mutation status of tumors.

It issues a quicker mutation status results which enable physicians to determine the course of treatment quickly.

Vall d’Hebron University Hospital Medical Oncology Department director head Professor Josep Tabernero said: "The speed at which the test results become available has helped us initiate effective treatments faster, which has led to improved patient outcomes."

Image: A view of the Vall d’Hebron University Hospital in Spain. Photo: courtesy of JT Curses.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact